Meiwei Biological - B (02493): Maiwei Health Injection supplementary indications application approved by the National Medical Products Administration.

MW Bioscience-B (02493) announced that its wholly-owned subsidiary, Jiangsu Taikang Biopharmaceutical Co., Ltd. (hereinafter referred to as "Taikang Biopharma"), has received the Approval Notice for Drug Supplementary Application issued by the National Medical Products Administration. The supplementary application for Denosumab Injection (Maiweijian, 9MW0321) to increase the indications for solid tumor bone metastasis and multiple myeloma (used in the treatment of patients with solid tumor bone metastasis or multiple myeloma to delay or reduce the risk of bone-related events such as pathological fractures, spinal cord compression, bone radiotherapy, or bone surgery) has been approved by the National Medical Products Administration.